Search results for "antico"

showing 10 items of 736 documents

Successful Treatment of Catastrophic Antiphospholipid Antibody Syndrome (CAPS) Associated With Splenic Marginal-zone Lymphoma With Low-molecular Weig…

2008

ABSTRACT Case report A 69-year-old woman with splenic marginal-zone lymphoma was admitted with progressive abdominal pain and splenomegaly as the suspected cause of pain. Rituximab treatment (375 mg/m 2 ) had been initiated on the day of admission. Abdominal computerized tomography revealed splenic infarction. Laboratory tests showed elevation of liver enzymes and creatinine, low platelet count, prolonged partial thromboplastin time, and lupus anticoagulant positivity. The diagnosis of catastrophic antiphospholipid antibody syndrome was made. Weight-adjusted low-molecular weight heparin therapy was initiated. Freedom from symptoms and normalization of liver enzymes and creatinine occurred w…

Bendamustinemedicine.medical_specialtyLymphoma B-Cellmedicine.drug_classLow molecular weight heparinAntineoplastic AgentsGastroenterologyAntibodies Monoclonal Murine-Derivedimmune system diseaseshemic and lymphatic diseasesInternal medicineBendamustine HydrochlorideHumansMedicineSplenic marginal zone lymphomaAgedLupus anticoagulantbusiness.industrySplenic NeoplasmsAnticoagulantAntibodies MonoclonalAnticoagulantsGeneral MedicineHeparinHeparin Low-Molecular-WeightAntiphospholipid Syndromemedicine.diseaseSurgerySplenic infarctionNitrogen Mustard CompoundsFemaleRituximabRituximabbusinessmedicine.drugThe American Journal of the Medical Sciences
researchProduct

Rufinamide in children and adults with Lennox-Gastaut syndrome: first Italian multicenter experience

2010

This is the first multicenter Italian experience with rufinamide as an adjunctive drug in children, adolescents and adults with Lennox-Gastaut syndrome. The patients were enrolled in a prospective, add-on, open-label treatment study from 11 Italian centers for children and adolescent epilepsy care. Forty-three patients (26 males, 17 females), aged between 4 and 34 years (mean 15.9 ± 7.3, median 15.0), were treated with rufinamide for a mean period of 12.3 months (range 3-21 months). Twenty patients were diagnosed as cryptogenic and 23 as symptomatic. Rufinamide was added to the baseline therapy at the starting dose of 10mg/kg body weight, evenly divided in two daily doses and then increased…

MalePediatricsLennox-Gastaut syndromeAtypical absence seizuresRufinamideLennox–Gastaut syndrome; Rufinamide; Orphan drug; Pediatrics; Epilepsy; Drop attacksInfantilePediatricsSpasmsEpilepsyRufinamideDrop attacks; Epilepsy; Lennox-Gastaut syndrome; Orphan drug; Pediatrics; Rufinamide; Adolescent; Adult; Anticonvulsants; Child; Child Preschool; Drug Therapy Combination; Female; Humans; Intellectual Disability; Italy; Lennox Gastaut Syndrome; Male; Spasms Infantile; Treatment Outcome; Triazoles; Valproic Acid; Young Adult; Neurology (clinical); NeurologyChildPediatricValproic AcidDrop attacksGeneral MedicineSettore MED/39 - Neuropsichiatria InfantileTreatment OutcomeItalyNeurologyAnesthesiaChild PreschoolCombinationVomitingAnticonvulsantsDrug Therapy CombinationFemalemedicine.symptomSpasms Infantilemedicine.drugAdultmedicine.medical_specialtyAdolescentClinical NeurologyIrritabilityYoung AdultDrug TherapyIntellectual DisabilitymedicineHumanspediatrics epilepsyPreschoolAdverse effectLennox–Gastaut syndrome; rufinamide; orphan drug; pediatrics epilepsy; drop attacks; refractory epilepsy.EpilepsyOrphan drugbusiness.industryLennox Gastaut SyndromeValproic Acidrefractory epilepsyTriazolesmedicine.diseaseNeurology (clinical)businessLennox–Gastaut syndromeLennox–Gastaut syndrome
researchProduct

Lemierre Syndrome: Clinical Update and Protocol for a Systematic Review and Individual Patient Data Meta-analysis.

2018

Lemierre syndrome usually affects otherwise healthy adolescents or young adults and occurs at an overall rate of 1 to 10 cases per million person-years with an estimated fatality rate of 4 to 9%. Diagnostic criteria remain debated and include acute neck/head bacterial infection (often tonsillitis caused by anaerobes at high potential for sepsis and vascular invasion, notably Fusobacterium necrophorum) complicated by local vein thrombosis, usually involving the internal jugular vein, and systemic septic embolism. Medical treatment is based on antibiotic therapy with anaerobic coverage, anticoagulant drugs and supportive care in case of sepsis. Surgical procedures can be required, including d…

AdultMalemedicine.medical_specialtyTonsillitisved/biology.organism_classification_rank.species030204 cardiovascular system & hematologySepsis03 medical and health sciencesYoung Adult0302 clinical medicineFusobacterium necrophorumJugular veinCase fatality ratemedicineHumansIntensive care medicine610 Medicine & healthInternal jugular veinSeptic embolismVenous Thrombosisbusiness.industryved/biologyAnticoagulantsHematologyLemierre Syndromemedicine.diseaseLemierre Study GroupPrognosisAnti-Bacterial AgentsVenous thrombosisFusobacterium necrophorumbusiness030215 immunologyHamostaseologie
researchProduct

The effect of two low doses of aspirin on whole blood thromboxane and prostacyclin generation in healthy subjects

1983

SummaryThe effects of two low doses of aspirin (20 mg and 100 mg) on prostacyclin and thromboxane formation during whole blood clotting were studied in 8 healthy volunteers.A single 100 mg aspirin dose caused more than 90% reduction of both serum TXB2 and 6-keto-PGF1α; a single 20 mg dose of aspirin inhibited serum TXB2 more than 6-keto-PGF1α but effects on these two products could not be completely dissociated.However, the effect of a single 20 mg aspirin dose on serum TXB2, was of much longer duration than its inhibitory effect on PGI2 synthesis during whole blood clotting.

AdultMalemedicine.medical_specialtyTime Factorsmedicine.drug_classThromboxaneAlpha (ethology)Prostacyclin6-Ketoprostaglandin F1 alphaInternal medicinemedicineHumansCyclooxygenase InhibitorsBlood CoagulationWhole bloodAspirinAspirinChemistryAnticoagulantLow doseThromboxanesHematologyHeparinEpoprostenolThromboxane B2EndocrinologyFemalelipids (amino acids peptides and proteins)circulatory and respiratory physiologymedicine.drug
researchProduct

Antithrombotics and new interventions for venous thromboembolism: Exploring possibilities beyond factor IIa and factor Xa inhibition.

2021

Abstract Direct oral anti–activated factor X and antithrombin agents have largely replaced vitamin K antagonists as the standard of care in treatment of venous thromboembolism. However, gaps in efficacy and safety persist, notably in end‐stage renal disease, implantable heart valves or assist devices, extracorporeal support of the circulation, and antiphospholipid syndrome. Inhibition of coagulation factor XI (FXI) emerges as a promising new therapeutic target. Antisense oligonucleotides offer potential advantages as a prophylactic or therapeutic modality, with one dose‐finding trial in orthopedic surgery already published. In addition, monoclonal antibodies blocking activation and/or activ…

medicine.drug_class2720 Hematologyvenous thromboembolism610 Medicine & healthBioinformaticslaw.inventionchemistry.chemical_compoundRandomized controlled trialAntiphospholipid syndromelawAntithromboticMedicineDiseases of the blood and blood-forming organsFactor XIIbusiness.industrycatheter(s)Factor X10031 Clinic for AngiologyAntithrombinAnticoagulantanticoagulantHematologycontact systemmedicine.diseasefactor XIPulmonary embolismchemistryRC633-647.5businessState of the Art Isth 2020medicine.drugResearch and practice in thrombosis and haemostasis
researchProduct

Influenza della correlazione seriale nell'analisi di trend in serie di variabili climatiche in Sicilia

2011

trend cambiamento climantico
researchProduct

Factors responsible for interindividual differences in the dose requirement of phenprocoumon

1987

The total and unbound plasma concentrations of phenprocoumon and the prothrombin complex activity were determined in 51 patients on phenprocoumon. A 7-fold difference in the dosing rate (10-70 micrograms/kg/day) was required to maintain the prothrombin complex activity at 11-30% of normal. The variation in dosing requirement was mainly due to interindividual differences in the intrinsic clearance of phenprocoumon and only to a minor degree to differences in sensitivity to it. On average patients with myocardial infarction required only 2/3 of the daily dose of phenprocoumon of post cardiac surgery patients and patients with thrombosis and emboli. That difference appeared to be due to higher…

Malemedicine.medical_specialtymedicine.drug_classIndividualityPhenprocoumonPharmacokineticsInternal medicinemedicineHumansPharmacology (medical)Myocardial infarctionDosingPharmacologyChemistryCoronary ThrombosisAnticoagulant4-HydroxycoumarinsGeneral MedicineMiddle Agedmedicine.diseaseThrombosisCardiac surgeryEndocrinologyPhenprocoumonProthrombin TimeCardiologyFemaleProtein Bindingmedicine.drugSurgical patientsEuropean Journal of Clinical Pharmacology
researchProduct

Survival and recurrent venous thromboembolism in patients with first proximal or isolated distal deep vein thrombosis and no pulmonary embolism

2017

Essentials The long-term risk of recurrence and death after distal deep vein thrombosis (DVT) is uncertain. We included subjects with first proximal or isolated distal DVT (IDDVT) and no pulmonary embolism. The risk of symptomatic and asymptomatic recurrence is lower after IDDVT (vs. proximal). IDDVT may be associated with a lower long-term risk of death, especially after unprovoked DVT. SummaryBackground A few studies have focused on the risk of recurrence after first acute isolated distal deep vein thrombosis (IDDVT) compared with proximal DVT (PDVT), whereas the incremental risk of death has never been explored beyond the first 3 years after acute event. Methods Our single-center cohort …

Malemedicine.medical_specialtyDeep veinKaplan-Meier Estimate030204 cardiovascular system & hematologyLower riskGastroenterologyAsymptomaticVeinsanticoagulation; death; distal deep vein thrombosis; pulmonary embolism; venous thromboembolism; Hematology03 medical and health sciences0302 clinical medicineRecurrenceRisk FactorsdeathInternal medicinemedicineHumans030212 general & internal medicineanticoagulationAgedVenous Thrombosisbusiness.industryMortality rateHazard ratioVenous ThromboembolismHematologyMiddle Agedmedicine.diseaseThrombosisSurgeryPulmonary embolismVenous thrombosisTreatment Outcomemedicine.anatomical_structureFemaledistal deep vein thrombosismedicine.symptomPulmonary EmbolismbusinessFollow-Up StudiesJournal of Thrombosis and Haemostasis
researchProduct

Antivitamin K Drugs in Stroke Prevention

2014

Among the different subtypes of ischaemic strokes, almost 20 % are of cardiac origin. Different are the causes of cardioembolic stroke, but the most common is the atrial fibrillation, a supraventricular arrhythmia. Appropriate use of antiplatelet drugs and anticoagulants after transient ischaemic attack (TIA) or ischaemic stroke depends on whether the underlying cause is cardioembolic or of presumed arterial origin. Adequate antiplatelet therapy is recommended for secondary prevention after cerebral ischaemia of presumed arterial origin, whether for patients with TIA and ischaemic stroke of cardiac origin, mainly due to atrial fibrillation. Vitamin K antagonists (VKAs) are highly effective …

medicine.medical_specialtyVitamin KSettore MED/09 - Medicina InternaAppropriate useInternal medicinemedicineAnimalsHumanscardiovascular diseasesRandomized Controlled Trials as TopicPharmacologySupraventricular arrhythmiabusiness.industryPatient choiceStandard treatmentAnticoagulantsVKAs Stroke preventionAtrial fibrillationmedicine.diseaseStrokeIschemic Attack TransientStroke preventionCardiologyCerebral ischaemiaCardiology and Cardiovascular MedicinebusinessPlatelet Aggregation InhibitorsDiscovery and development of direct thrombin inhibitorsCurrent Vascular Pharmacology
researchProduct

Disposition and Anticoagulant Activity of the Enantiomers of Phenprocoumon in Phenobarbital Pretreated Rats

1978

The purpose of this study was to assess in rats the effect of enzyme induction on the stereoselective disposition and anticoagulant activity of phenprocoumon.

PhenprocoumonbiologyChemistrybiology.proteinmedicineStereoselectivityPhenobarbitalDispositionEnzyme inducerPharmacologyEnantiomerAnticoagulant activitymedicine.drug
researchProduct